A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpoint
{{output}}
Phase II oncology trials often face challenges such as patient recruitment difficulties and limited resources, leading to the use of single-arm designs without concurrent controls. This study introduces a novel two-stage Bayesian design bridging single-arm and... ...
